BR112022014633A2 - Anticorpos anti-integrina alfavbeta8 para uso no tratamento de doença renal - Google Patents
Anticorpos anti-integrina alfavbeta8 para uso no tratamento de doença renalInfo
- Publication number
- BR112022014633A2 BR112022014633A2 BR112022014633A BR112022014633A BR112022014633A2 BR 112022014633 A2 BR112022014633 A2 BR 112022014633A2 BR 112022014633 A BR112022014633 A BR 112022014633A BR 112022014633 A BR112022014633 A BR 112022014633A BR 112022014633 A2 BR112022014633 A2 BR 112022014633A2
- Authority
- BR
- Brazil
- Prior art keywords
- integrin
- antibodies
- kidney disease
- avß8
- kidney
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ANTICORPOS ANTI-INTEGRINA ALFAvBETA8 PARA USO NO TRATAMENTO DE DOENÇA RENAL. A presente invenção refere-se a métodos e composições para tratar doença renal, como doença renal crônica (DRC), em que os métodos e composições compreendem anticorpos ou um fragmento de ligação ao antígeno dos mesmos que se ligam específica e seletivamente à integrina avß8 humana, que foi constatada, conforme descrito, como sendo altamente expressa em tecido e células renais, e, em particular, tecido renal doente ou fibrótico. Os anticorpos anti-integrina avß8 revelados se ligam à integrina avß8 humana no rim e bloqueiam a ativação de TGF-ß a partir de sua forma latente no tecido renal. Os anticorpos anti-avß8 nos métodos revelados reduzem, atenuam ou anulam fibrose renal, que é associada às atividades de integrina avß8 e TGF-ß no tecido renal. Os anticorpos e métodos revelados tratam eficazmente doença renal, em particular, fibrose associada à doença renal, como DRC, em indivíduos em necessidade dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966258P | 2020-01-27 | 2020-01-27 | |
PCT/EP2021/051753 WO2021151889A1 (en) | 2020-01-27 | 2021-01-26 | ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022014633A2 true BR112022014633A2 (pt) | 2022-09-13 |
Family
ID=74561850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022014633A BR112022014633A2 (pt) | 2020-01-27 | 2021-01-26 | Anticorpos anti-integrina alfavbeta8 para uso no tratamento de doença renal |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230112035A1 (pt) |
EP (1) | EP4096785A1 (pt) |
JP (1) | JP2023511686A (pt) |
KR (1) | KR20220132567A (pt) |
CN (1) | CN115151305A (pt) |
AR (1) | AR121193A1 (pt) |
AU (1) | AU2021213403A1 (pt) |
BR (1) | BR112022014633A2 (pt) |
CA (1) | CA3167390A1 (pt) |
CL (1) | CL2022001999A1 (pt) |
CO (1) | CO2022011661A2 (pt) |
CR (1) | CR20220392A (pt) |
EC (1) | ECSP22066085A (pt) |
IL (1) | IL294814A (pt) |
MX (1) | MX2022009165A (pt) |
TW (1) | TW202140554A (pt) |
WO (1) | WO2021151889A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024056668A1 (en) | 2022-09-12 | 2024-03-21 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CN105315370A (zh) * | 2010-02-18 | 2016-02-10 | 加利福尼亚大学董事会 | 整合素αVβ8中和抗体 |
WO2013026004A2 (en) | 2011-08-17 | 2013-02-21 | The Regents Of The University Of California | Antibodies that bind integrin alpha-v beta-8 |
EP3157561B1 (en) | 2014-06-17 | 2019-12-18 | MedImmune Limited | Improved alpha-v beta-8 antibodies |
EP3634485A4 (en) * | 2017-06-07 | 2021-07-21 | Silverback Therapeutics, Inc. | CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES |
-
2021
- 2021-01-13 TW TW110101209A patent/TW202140554A/zh unknown
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 JP JP2022545136A patent/JP2023511686A/ja active Pending
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 AU AU2021213403A patent/AU2021213403A1/en active Pending
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en active Application Filing
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Search and Examination
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022011661A2 (es) | 2022-08-30 |
JP2023511686A (ja) | 2023-03-22 |
AU2021213403A1 (en) | 2022-09-15 |
CN115151305A (zh) | 2022-10-04 |
ECSP22066085A (es) | 2022-09-30 |
CL2022001999A1 (es) | 2023-01-27 |
AR121193A1 (es) | 2022-04-27 |
CR20220392A (es) | 2022-09-07 |
KR20220132567A (ko) | 2022-09-30 |
CA3167390A1 (en) | 2021-08-05 |
TW202140554A (zh) | 2021-11-01 |
WO2021151889A1 (en) | 2021-08-05 |
MX2022009165A (es) | 2022-08-16 |
IL294814A (en) | 2022-09-01 |
US20230112035A1 (en) | 2023-04-13 |
EP4096785A1 (en) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022014633A2 (pt) | Anticorpos anti-integrina alfavbeta8 para uso no tratamento de doença renal | |
BR112012013734A2 (pt) | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. | |
PH12018502046A1 (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
BR112022004474A8 (pt) | Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta | |
BR112012010261A2 (pt) | dispositivo de microcânula, e, métodos para tratar o espaço supracoroidal de um olho, para tratar a região posterior de um olho e para tratar os tecidos dentro ou adjacentes ao espaço supracoroidal de um olho | |
EA201691482A1 (ru) | Человеческие антитела к pd-1 | |
BR112015020788A2 (pt) | métodos de tratamento da lesão renal aguda | |
PA8849001A1 (es) | Anticuerpos de c-met | |
BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
BR112017027549A2 (pt) | anticorpo para cd40 | |
EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
EA201591762A1 (ru) | Человеческие антитела к grem1 | |
BR112014018471A2 (pt) | anticorpos anti-ige m1' e métodos para o seu uso | |
BR112015003459A2 (pt) | moléculas com atividade de ligação ao antígeno e de ligação ao receptor fc gama polivalente | |
BR112014016299A8 (pt) | imunoglobulinas de domínio variável e usos das mesmas | |
BR112016018205A2 (pt) | métodos de tratamento de mal de alzheimer | |
ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
BR112021025077A2 (pt) | Anticorpos anti-sortilina para uso em terapia | |
EA202190094A1 (ru) | Антитела против cd40 для применения в лечении аутоиммунного заболевания | |
BR112017019071A2 (pt) | método para tratar colangite esclerosante primária | |
Abilasha et al. | Dermatoglyphics: a predictor tool to analyze the occurrence of breast cancer | |
BR112015022025A2 (pt) | método de tratamento de infecções, doenças ou desordens de unidade de unha |